<DOC>
	<DOCNO>NCT01446042</DOCNO>
	<brief_summary>The purpose study determine efficacy ( base pharmacokinetic profile testosterone ) safety TBS-1 treatment hypogonadal men</brief_summary>
	<brief_title>Safety Efficacy Intranasal TBS-1 Treatment Male Hypogonadism</brief_title>
	<detailed_description>This study 4 Period study consist 16 visit overnight clinic stay span year help determine efficacy TBS-1 gel administer twice daily ( b.i.d ) three time daily ( t.i.d ) In addition , study investigate safety tolerability TBS-1 90 , 180 360 day treatment .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Eunuchism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria Male 18 80 year age Able understand provide sign informed consent Have 2 fast morning ( 0900 h ± 30 min ) serum total testosterone level &lt; 300 ng/dL Body mass index 18.5 kg/m2 35 kg/m2 Hemoglobin level &gt; = 13.0 g/dL Screening laboratory assessment within ±15 % normal range , exception liver function test ( need within normal range ) HbA1c ( must &lt; 7.0 % [ 9.5 mmol/L ] ) ; lipid profile endocrine profile assessment also exempt range unless assessment indicate significant intercurrent illness testosterone deficiency Ear , nose throat examination include nasal endoscopy without clinically significant abnormal finding Normal prostate age base digital rectal exam serum PSA &lt; 4.0 ng/mL . Exclusion Criteria Significant intercurrent disease type , particular liver , kidney , heart disease , psychiatric illness Hyperparathyroidism , uncontrolled diabetes mellitus , hypothyroidism , hyperthyroidism ( thyroid stimulate hormone &lt; 1.5 time upper limit normal ) Hematocrit &gt; 54 % screen History pituitary hypothalamic tumor history malignancy within past 5 year , exclude basal cell squamous cell carcinoma skin curatively treat surgery History nasal surgery , specifically turbinoplasty , septoplasty , rhinoplasty , `` nose job , '' sinus surgery History nasal fracture within past 6 month and/or prior nasal fracture cause severely deviated anterior nasal septum Active allergy , rhinitis , rhinorrhea , nasal congestion Mucosal inflammatory disorder , specifically pemphigus Sjogren 's syndrome Sinus disease , specifically acute sinusitis , chronic sinusitis , allergic fungal sinusitis History nasal disorder ( eg , polyposis , recurrent epistaxis [ &gt; 1 nose bleed per month ] , abuse nasal decongestant ) sleep apnea Use form intranasal medication delivery , specifically nasal corticosteroid oxymetazolinecontaining nasal spray ( eg , Dristan® 12Hour Nasal Spray ) History severe adverse drug reaction leukopenia A known hypersensitivity lidocaine material may use study History abnormal bleeding tendency thrombophlebitis unrelated venipuncture intravenous cannulation History hepatitis B , positive test hepatitis B surface antigen , history hepatitis C , positive test hepatitis C antibody Presence human immunodeficiency virus infection antibody History asthma ongoing asthma treatment History sleeping problem shift worker Smoker &gt; 10 cigarette ( equivalent ) per day Regular consumption 4 unit alcohol daily ( 1 unit define 300 mL beer , 1 glass wine , 1 measure spirit ) difficulty abstain alcohol 48 hour prior 24 hour blood sample visit History current evidence abuse alcohol drug substance , licit illicit , positive urine drug alcohol screen Treatment androgen therapy within least 2 week prior baseline evaluation ( subject androgen therapy require washout period 4 week depot product administer intramuscularly [ eg , testosterone enanthate 200 mg/mL ] 2 week product administer orally topically [ oral , patch , gel , buccal ] ) Current treatment androgen ( eg , dehydroepiandrosterone [ DHEA ] ) , anabolic steroid , sex hormone Treatment estrogen , gonadotropinreleasing hormone ( GnRH ) agonists , growth hormone within previous 12 month Treatment drug interfere metabolism testosterone , anastrozole , clomiphene , dutasteride , finasteride , flutamide , ketoconazole , spironolactone , testolactone Treatment antihypertensive , antidepressant , tranquilizer , histamine 2 ( H2 ) receptor blocker part stable regimen ( stable dose least 3 month prior baseline ) ; Poor compliance history low likelihood maintain attendance Participation research study conduct study 30 day prior initiation study blood donation time study within 12 week period prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>